Anti-inflammatory effect of an insulin infusion in patients on maintenance haemodialysis: A randomized controlled pilot study

Nephrology

Volumn 16, Issue 1, 2011, Pages 68-75

  Vos, Frederiek E ^a   Manning, Patrick J ^a   Sutherland, Wayne Hf ^a   Schollum, John B ^b   Walker, Robert J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b DUNEDIN HOSPITAL   (New Zealand)

Author keywords

C reactive protein; haemodialysis; inflammation; insulin; oxidative stress

Indexed keywords

C REACTIVE PROTEIN; DITYROSINE; GLUCOSE; INSULIN; INTERLEUKIN 6; NEOPTERIN; PEROXIDE; THIOL DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CROSSOVER PROCEDURE; FEMALE; HEMODIALYSIS; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; FEMALE; HUMANS; INFLAMMATION; INSULIN; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPTERIN; NEW ZEALAND; PEROXIDES; PILOT PROJECTS; RENAL DIALYSIS; SINGLE-BLIND METHOD; SULFHYDRYL COMPOUNDS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; VASCULAR CELL ADHESION MOLECULE-1;

EID: 78650645770     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2010.01329.x     Document Type: Article

References (45)

1. Schiffrin EL, Lipman ML, Mann JF, Schiffrin EL, Lipman ML, Mann JFE,. Chronic kidney disease: Effects on the cardiovascular system. Circulation 2007; 116: 85-97.
2. Parfrey PS, Foley RN,. The clinical epidemiology of cardiac disease in chronic renal failure. J. Am. Soc. Nephrol. 1999; 10: 1606-15.
3. Baigent C, Burbury K, Wheeler D,. Premature cardiovascular disease in chronic renal failure [see comment]. Lancet 2000; 356: 147-52.
4. Zoccali C, Mallamaci F, Tripepi G, Zoccali C, Mallamaci F, Tripepi G,. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol. Dial. Transplant. 2004; 19 (Suppl 5): V67-72.
5. Ross R,. Atherosclerosis-an inflammatory disease [see comment]. N. Engl. J. Med. 1999; 340: 115-26. (Pubitemid 29054847)
6. Galli F,. Protein damage and inflammation in uraemia and dialysis patients. Nephrol. Dial. Transplant. 2007; 22 (Suppl 5): v20-36.
7. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004; 65: 1009-16.
8. Hakim RM, Held PJ, Stannard DC, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int. 1996; 50: 566-70.
9. Nguyen-Khoa T, Massy ZA, De Bandt JP, et al. Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol. Dial. Transplant. 2001; 16: 335-40.
10. Pupim LB, Himmelfarb J, McMonagle E, et al. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress [see comment]. Kidney Int. 2004; 65: 2371-9.
11. Walker RJ, Sutherland WH, De Jong SA, Sutherland WHF,. Effect of changing from a cellulose acetate to a polysulphone dialysis membrane on protein oxidation and inflammation markers. Clin. Nephrol. 2004; 61: 198-206.
12. Arici M, Walls J,. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int. 2001; 59: 407-14.
13. Zoccali C, Tripepi G, Mallamaci F, Zoccali C, Tripepi G, Mallamaci F,. Predictors of cardiovascular death in ESRD. Semin. Nephrol. 2005; 25: 358-62.
14. Dandona P, Chaudhuri A, Ghanim H, Mohanty P,. Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose. Semin. Thorac. Cardiovasc. Surg. 2006; 18: 293-301.
15. Dandona P, Chaudhuri A, Ghanim H, Mohanty P,. Insulin as an anti-inflammatory and antiatherogenic modulator. J. Am. Coll. Cardiol. 2009; 53: S14-20.
16. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect? J. Clin. Endocrinol. Metab. 2001; 86: 3257-65.
17. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU [see comment]. N. Engl. J. Med. 2006; 354: 449-61.
18. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients [see comment]. N. Engl. J. Med. 2001; 345: 1359-67.
19. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: A meta-analysis including NICE-SUGAR study data. CMAJ 2009; 180: 821-7.
20. Van den Berghe G, Mesotten D, Vanhorebeek I,. Intensive insulin therapy in the intensive care unit. CMAJ 2009; 180: 799-800.
21. Malmberg K,. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group [see comment]. BMJ 1997; 314: 1512-15.
22. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year [see comment]. J. Am. Coll. Cardiol. 1995; 26: 57-65.
23. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur. Heart J. 2005; 26: 650-61.
24. Ritchie-McLean S, Kirwan C, Levy JB, Ritchie-McLean S, Kirwan C, Levy JB,. Is there a role for intensive insulin therapy in patients with kidney disease? Am. J. Kidney Dis. 2007; 50: 371-8.
25. Mak RH, DeFronzo RA,. Glucose and insulin metabolism in uremia [see comment]. Nephron 1992; 61: 377-82.
26. Koster JF, Biemond P, Swaak AJ,. Intracellular and extracellular sulphydryl levels in rheumatoid arthritis. Ann. Rheum. Dis. 1986; 45: 44-6.
27. Witko-Sarsat V, Gausson V, Nguyen AT, et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: A potential target for N-acetylcysteine treatment in dialysis patients [see comment]. Kidney Int. 2003; 64: 82-91.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ,. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
29. Tatzber F, Griebenow S, Wonisch W, et al. Dual method for the determination of peroxidase activity and total peroxides-iodide leads to a significant increase of peroxidase activity in human sera. Anal. Biochem. 2003; 316: 147-53.
30. Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J. Clin. Endocrinol. Metab. 2003; 88: 1082-8.
31. Chaudhuri A, Janicke D, Wilson MF, et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 2004; 109: 849-54.
32. Wong VW, McLean M, Boyages SC, Cheung NW,. C-reactive protein levels following acute myocardial infarction: effect of insulin infusion and tight glycemic control. Diabetes Care 2004; 27: 2971-3.
33. Visser L, Zuurbier CJ, Hoek FJ, et al. Glucose, insulin and potassium applied as perioperative hyperinsulinaemic normoglycaemic clamp: Effects on inflammatory response during coronary artery surgery. Br. J. Anaesth. 2005; 95: 448-57.
34. Parikh SV, Abdullah SM, Keeley EC, et al. Effect of glucose-insulin- potassium (GIK) infusion on biomarkers of cardiovascular risk in ST elevation myocardial infarction (STEMI): Insight into the failure of GIK. Diab. Vasc. Dis. Res. 2007; 4: 222-5.
35. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial [see comment]. JAMA 2005; 293: 437-46.
36. Dandona P, Chaudhuri A, Mohanty P, Ghanim H,. Anti-inflammatory effects of insulin. Curr. Opin. Clin. Nutr. Metab. Care 2007; 10: 511-17.
37. Pepys MB, Hirschfield GM,. C-reactive protein: A critical update. [erratum appears in J Clin Invest. 2003 Jul; 112(2):299]. J. Clin. Invest. 2003; 111: 1805-12.
38. Himmelfarb J, McMonagle E, McMenamin E,. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int. 2000; 58: 2571-8.
39. Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease [see comment]. Nature 2006; 440: 1217-21.
40. Abe M, Kaizu K, Matsumoto K,. Evaluation of the hemodialysis-induced changes in plasma glucose and insulin concentrations in diabetic patients: Comparison between the hemodialysis and non-hemodialysis days. Ther. Apher. Dial. 2007; 11: 288-95.
41. Abe M, Kaizu K, Matsumoto K,. Plasma insulin is removed by hemodialysis: Evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. Ther. Apher. Dial. 2007; 11: 280-87.
42. Festa A, D'Agostino R Jr, Mykkanen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler. Thromb. Vasc. Biol. 1999; 19: 562-8.
43. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease [see comment]. N. Engl. J. Med. 1996; 334: 952-7.
44. Leonetti F, Iozzo P, Giaccari A, et al. Absence of clinically overt atherosclerotic vascular disease and adverse changes in cardiovascular risk factors in 70 patients with insulinoma. J. Endocrinol. Invest. 1993; 16: 875-80.
45. Kerr PG, Sutherland WHF, de Jong S, Vaithalingham I, Williams SM, Walker RJ,. The impact of standard high-flux polysulfone versus novel high-flux polysulfone dialysis membranes on inflammatory markers: A randomized, single-blinded, controlled clinical trial. Am. J. Kidney Dis. 2007; 49: 533-9.